Guillain-Barré syndrome and related diseases after influenza virus infection

Masaki Yamana, MD, Motoi Kuwahara, MD, PhD, Yuta Fukumoto, MD, Keisuke Yoshikawa, MD, Kazuo Takada, MD, PhD, and Susumu Kusunoki, MD, PhD

Neurol Neuroimmunol Neuroinflamm 2019;6:e575. doi:10.1212/NXI.0000000000000575

Abstract

Objective
We examined the clinical and serologic features of Guillain-Barré syndrome (GBS)-related diseases (GBSRDs), including GBS, Fisher syndrome (FS), and Bickerstaff brainstem encephalitis (BBE), after influenza virus infection (GBSRD-I) to reveal potential underlying autoimmune mechanisms.

Methods
We retrospectively investigated the presence of antiglycolipid antibodies against 11 glycolipids and the clinical features of 63 patients with GBSRD-I. Autoantibody profiles and clinical features were compared with those of 82 patients with GBSRDs after Campylobacter jejuni infection (GBSRD-C).

Results
The anti-GQ1b seropositivity rate was significantly higher, whereas the GM1 and GD1a seropositivity rates were significantly lower in GBSRD-I compared with GBSRD-C. Anti-GQ1b and anti-GT1a were the most frequently detected antiglycolipid antibodies in GBSRD-I (both 15/63, 24%). Consequently, FS was more frequent in GBSRD-I than GBSRD-C (22% vs 9%, p < 0.05). In addition, as for GBS, cranial nerve deficits, sensory disturbances, and ataxia were more frequent in the cases after influenza infection (GBS-I) than in those after C. jejuni infection (GBS-C) (46% vs 15%, 75% vs 46%, and 29% vs 4%, respectively; all p < 0.01). Nerve conduction studies revealed acute inflammatory demyelinating polyneuropathy (AIDP) in 60% of patients with GBS-I but only 25% of patients with GBS-C (p < 0.01).

Conclusions
Anti-GQ1b antibodies are the most frequently detected antibodies in GBSRD-I. Compared with GBS-C, GBS-I is characterized by AIDP predominance and frequent presence of cranial nerve involvement and ataxia.
Guillain-Barré syndrome (GBS) is an acute acquired autoimmune disorder of the peripheral nerves that frequently develops after infection. For instance, antecedent infection such as Campylobacter jejuni, cytomegalovirus, or Mycoplasma pneumoniae is observed in approximately 70% of patients with GBS. Alternatively, GBS following influenza virus infection (GBS-I) is relatively rare.\(^1\) However, influenza virus infection is a common respiratory syndrome across all age groups. Influenza is also known to cause neurologic complications such as encephalitis, encephalopathy, and Reye syndrome that require differential diagnosis.\(^2\) In addition, several reports have shown that influenza virus infection or influenza-like illness can also cause Fisher syndrome (FS) and Bickerstaff brainstem encephalitis (BBE),\(^3\) which are caused by the pathogenic mechanisms similar to those of GBS. Here, we call GBS, FS, and BBE as GBS-related diseases (GBSRDs).

Antiglycolipid antibodies are elevated in GBSRD and are strongly implicated in the pathogenesis. Antibodies against GMI on the neuronal membrane ganglioside are often detected in GBS after C. jejuni infection, and antibodies to galactocerebroside (Gal-C) are often detected in neurologic diseases following M. pneumoniae infection.\(^6\) The structures of these carbohydrates are similar to carbohydrates expressed by the infectious agents, suggesting that a form of molecular mimicry is responsible for GBS-associated autoimmunity.\(^8\) In contrast to GBS associated with C. jejuni and M. pneumoniae infection, the clinical and serologic features of GBSRD and GBS after influenza virus infection (GBSRD-I and GBS-I, respectively) have not been described in detail. The purpose of this study is to investigate the unique clinical and serologic features of GBSRD-I and GBS-I.

**Methods**

**Patients with GBSRD-I**

We collected clinical information and acute-phase serum samples from consecutive patients who are diagnosed with GBSRD-I. These serum samples were sent to our laboratory from multiple hospitals in Japan between October 2009 and February 2017 for the examination of antiglycolipid antibodies. GBS and BBE were diagnosed according to previously presented criteria,\(^10,11\) and FS was diagnosed according to the clinical triad of acute progressive ophthalmoplegia, ataxia, and areflexia without limb weakness or impairment of consciousness. Patients with the FS triad and limb weakness were included in the GBS subgroup. In all patients with GBSRD, influenza virus infection was diagnosed by an immunochromatography-based rapid influenza diagnostic test (RIDT) within 4 weeks of the onset of symptoms. Immunochromatography-based RIDT detects nucleoprotein, which is one of the most abundant proteins in influenza virus and has fewer mutations than hemagglutinin (HA) and neuraminidase (NA). Although there are some differences in the detection rate, RIDT can detect various subtypes of influenza virus such as H1N1, H3N2, type B seasonal viruses, and pandemic H1N1 2009 viruses.\(^12\) The sensitivity of the RIDTs is approximately 60%, and the specificity is higher than 95%.\(^13\) Patients with GBSRD-I with antecedent gastrointestinal infectious symptoms were excluded from the study.

**Clinical and electrophysiological assessment**

The clinical and electrophysiological data of each patient with GBS were obtained retrospectively from the original attending neurologist or pediatrician using a questionnaire. According to the Ho criteria, nerve conduction study (NCS) findings were used to classify cases as acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), or unclassified.\(^14\) NCS were

---

**Table 1 Demographic and basic clinical features of the GBSRD-I and GBSRD-C groups**

|                       | GBSRD-I (n = 63) | GBSRD-C (n = 82) | \(p\) Values |
|-----------------------|-----------------|-----------------|------------|
| **Age, median [range] (y)** | 40 [3–83]          | 30.5 [3–87]        | NS         |
| **Sex (male/female)** | 36/27 | 41/41 | NS |
| **Type of influenza virus (A/B/unknown)** | 37/17/10\(^a\) | NA | NS |
| **GBS/FS/BBE** | 48/14/1 | 74/7/1 | <0.05\(^b\) |
| **Delay between infection and GBS onset median [range] (d)** | (n = 61)\(^c\) 10 [2–28] | (n = 76)\(^d\) 9 [2–28] | NS |

Abbreviations: BBE = Bickerstaff brainstem encephalitis; FS = Fisher syndrome; GBS = Guillain-Barré syndrome; GBSRD = Guillain-Barré syndrome–related disease; GBSRD-C = Guillain-Barré syndrome–related disease after C. jejuni infection; GBSRD-I = Guillain-Barré syndrome–related disease after influenza virus infection; HA = hemagglutinin; NA = neuraminidase; NCS = nerve conduction study; RIDT = rapid influenza diagnostic test.

---

\(^a\) One patient was infected with both A and B influenza viruses. The number of days until onset was 8 after influenza A and 18 after influenza B.

\(^b\) FS was significantly more frequent in GBSRD-I than GBSRD-C.

\(^c\) In the GBSRD-I group, the patient with both influenza A and B and a patient with unclear delay from influenza to GBS onset were excluded (n = 2 of 63). In the GBSRD-C group, patients with unclear delay between influenza and GBS onset were excluded (n = 6 of 82).

---

**Glossary**

| AIDP = acute inflammatory demyelinating polyneuropathy; AMAN = acute motor axonal neuropathy; BBE = Bickerstaff brainstem encephalitis; FS = Fisher syndrome; GBS = Guillain-Barré syndrome; GBS-C = Guillain-Barré syndrome after C. jejuni infection; GBS-I = Guillain-Barré syndrome after influenza virus infection; GBSRD = Guillain-Barré syndrome–related disease; GBSRD-C = Guillain-Barré syndrome–related disease after C. jejuni infection; GBSRD-I = Guillain-Barré syndrome–related disease after influenza virus infection; HA = hemagglutinin; NA = neuraminidase; NCS = nerve conduction study; RIDT = rapid influenza diagnostic test. |
performed at each participating hospital in a median of 8.5 days (range [1–20] days) after GBS symptom onset.

**Antiglycolipid antibodies**

Serum IgG antibodies to 11 glycolipid antigens (GM1, GM2, GM3, GD1a, GD1b, GD3, GT1b, GQ1b, GT1a, Gal-C, and GalNac-GD1a) were examined in all patients by ELISA, as previously described. 15

**Patients with GBSRD-C**

Clinical and serologic features of GBSRD-I and GBS-I were compared with those of GBSRD and GBS after *C. jejuni* infection (GBSRD-C and GBS-C, respectively). The antiglycolipid antibodies of these patients with GBSRD-C were tested in our laboratory between September 2012 and April 2017. *C. jejuni* infection was diagnosed by fecal culture or *C. jejuni* antibody test.

**Statistical analysis**

Differences in proportions were evaluated using the χ2 test or Fisher exact test, and differences in the median were evaluated using the Mann-Whitney U test. p < 0.05 (2 tailed) was considered significant for all tests. Statistical calculations were performed using SPSS version 2.0 (IBM, Japan).

**Study approval and patient consent**

This study was approved by the Internal Review Board of Kindai University Faculty of Medicine. All participants provided written informed consent.

**Table 2** Comparison of antiglycolipid antibody profile between patients with GBSRD-I and GBSRD-C

| IgG antibody positive | GBSRD-I |  | GBSRD-C |  |
|----------------------|---------|---|---------|---|
|                      | All (n = 63) | GBS-I (n = 48) | FS-I (n = 14) | BBE-I (n = 1) | All (n = 82) | GBS-C (n = 74) | FS-C (n = 7) | BBE-C (n = 1) | p Values (GBSRD-I vs GBSRD-C) |
| Overall, n (%)       | 25 (40%) | 14 (29%) | 10 (71%) | 1 (100%) | 51 (62%) | 44 (59%) | 6 (86%) | 1 (100%) | <0.01 |
| GM1                  | 3 (5%)  | 3 (6%)  | 0 (0%)  | 0 (0%)  | 24 (29%) | 23 (31%) | 1 (14%) | 0 (0%) | <0.01 |
| GM2                  | 0 (0%)  | 0 (0%)  | 0 (0%)  | 0 (0%)  | 5 (6%)  | 5 (7%)  | 0 (0%)  | 0 (0%) | NS |
| GM3                  | 1 (2%)  | 0 (0%)  | 1 (7%)  | 0 (0%)  | 0 (0%)  | 0 (0%)  | 0 (0%)  | 0 (0%) | NS |
| GD1a                 | 1 (2%)  | 1 (2%)  | 0 (0%)  | 0 (0%)  | 18 (22%) | 16 (22%) | 1 (14%) | 1 (100%) | <0.01 |
| GD1b                 | 9 (14%) | 7 (15%) | 2 (13%) | 0 (0%)  | 12 (15%) | 12 (16%) | 0 (0%)  | 0 (0%) | NS |
| GD3                  | 2 (3%)  | 0 (0%)  | 1 (7%)  | 1 (100%) | 1 (11%)  | 1 (11%)  | 0 (0%)  | 0 (0%) | NS |
| GT1a                 | 15 (24%) | 4 (8%)  | 10 (71%) | 1 (100%) | 15 (18%) | 9 (12%)  | 5 (71%)  | 1 (100%) | NS |
| GT1b                 | 0 (0%)  | 0 (0%)  | 0 (0%)  | 0 (0%)  | 3 (4%)  | 1 (11%)  | 1 (14%)  | 1 (100%) | NS |
| GQ1b                 | 15 (24%) | 4 (8%)  | 10 (71%) | 1 (100%) | 7 (9%)  | 2 (3%)  | 4 (57%)  | 1 (100%) | <0.05 |
| GalNAc-GD1a          | 8 (13%) | 6 (13%) | 1 (7%)  | 1 (100%) | 17 (21%) | 16 (22%) | 1 (14%)  | 0 (0%) | NS |
| Gal-C                | 3 (5%)  | 3 (6%)  | 0 (0%)  | 0 (0%)  | 1 (1%)  | 0 (0%)  | 1 (14%)  | 0 (0%) | NS |

Abbreviations: BBE-C = Bickerstaff brainstem encephalitis after *C. jejuni* infection; BBE-I = Bickerstaff brainstem encephalitis after influenza virus infection; FS-C = Fisher syndrome after *C. jejuni* infection; FS-I = Fisher syndrome after influenza virus infection; GBS-C = Guillain-Barre syndrome after *C. jejuni* infection; GBS-I = Guillain-Barre syndrome after influenza virus infection; GBSRD-C = Guillain-Barre syndrome-related disease after *C. jejuni* infection; GBSRD-I = Guillain-Barre syndrome-related disease after influenza virus infection; NA = not applicable; NS = not significant.

**Data availability**

Anonymized data not published within the article will be shared by request from any qualified investigator.

**Results**

**Comparison of GBS subtype and antiglycolipid antibody profile between GBSRD-I and GBSRD-C**

The classic form of GBS (GBS-I or GBS-C according to the antecedent pathogen) was the most common disease subtype in both GBSRD-I and GBSRD-C groups (48/63 [76%] vs 74/82 [90%]), while BBE was rare in both groups (1 patient per group). In contrast, FS was significantly more prevalent in the GBSRD-I group compared with the GBSRD-C group (14/63 [22%] vs 7/82 [9%], p = 0.02). Antiglycolipid antibodies were detected more frequently in patients with GBSRD-C than in patients with GBSRD-I (51/82 [62%] vs 25/63 [40%]; p < 0.01) (table 1). There were also significant differences in seropositivity rates for specific antiglycolipid antibodies between groups. Anti-GM1 antibody was substantially more common in GBSRD-C than in GBSRD-I (24/82 [29%] vs 3/63 [5%]; p < 0.01). Similarly, seropositivity for anti-GD1a was more frequent in GBSRD-C (18/62 [22%] vs 1/63 [2%]; p < 0.01). In contrast, anti-GQ1b was significantly more frequent in GBSRD-I than in GBSRD-C (15/63 [24%] vs 7/82 [9%]; p < 0.05). Anti-GT1a was also relatively common in GBSRD-I (24%), although the seropositivity rate did not
Conversely, cranial nerve de\textit{ficiency} antibody seropositivity rate (29% vs 59%, patients with GBS-I) demonstrated a substantially lower anti-Gal-C antibody positive rate and the frequency of FS cases were lower, and the anti-Gal-C antibody positive rate was higher than in GBSRD-C. The proportion with AIDP was significantly higher in the GBS-I subgroup than in the GBS-C subgroup ($p < 0.01$). Among patients with GBS-I, there were no significant differences in demographic or clinical features between those infected with influenza virus A or B.

**Discussion**

GBSRD is presented after not only gastrointestinal infection but also upper respiratory infection. However, most of the antecedent infectious agents of upper respiratory infection are not identified. In the present study, we focused on influenza virus infection and report the distinct clinical and serologic features of GBSRD-I and GBS-I.

Anti-GQ1b and anti-GT1a were the most frequently detected antiglycolipid antibodies in GBSRD-I. GQ1b is densely localized in the paranodal regions of III, IV, and VI human cranial nerves. Therefore, anti-GQ1b antibody can cause ophthalmoplegia, which is one of the major symptoms of FS.\textsuperscript{16} In accord with this, FS was more frequent in GBSRD-I than GBSRD-C.

Compared with GBS-C, GBS-I is characterized by more frequent cranial nerve deficits, sensory disturbances, and ataxia. In addition, NCS findings revealed demyelinating neuropathy in a higher proportion of GBS-I cases than GBS-C cases. Furthermore, the frequency of AIDP was higher in GBS-I than in all GBS cases previously reported by a prospective cohort study in Japan (60% vs 40%).\textsuperscript{17} This is compatible with the results that GM1 and GD1a seropositivity rates were significantly more frequent in GBS-I than in GBS-C (46% vs 15%, 75% vs 46%, and 29% vs 4%, respectively; $p < 0.01$). There were no significant differences in age, sex, ratio, autonomic disturbance frequency, and the requirement for artificial ventilation between GBS-I and GBS-C subgroups.

We also obtained the NCS findings from 30 patients with GBS-I. According to the Ho criteria, 18 cases were classified as AIDP and 12 were unclassified, whereas no case was classified as AMAN. The proportion with AIDP was significantly higher in the GBS-I subgroup than in the GBS-C subgroup ($p < 0.01$). Among patients with GBS-I, there were no significant differences in demographic or clinical features between those infected with influenza virus A or B.

**Clinical features of GBS-I**

The clinical features of GBS-I ($n = 48$) and GBS-C are summarized in table 3. Compared with patients with GBS-C, patients with GBS-I demonstrated a substantially lower antiglycolipid antibody seropositivity rate (29% vs 59%, $p < 0.01$). Conversely, cranial nerve deficits, sensory disturbances, and ataxia were significantly more frequent in GBS-I than in GBS-C (46% vs 15%, 75% vs 46%, and 29% vs 4%, respectively; $p < 0.01$). There were no significant differences in age, sex ratio, autonomic disturbance frequency, and the requirement for artificial ventilation between GBS-I and GBS-C subgroups.

Compared with GBS-C, GBS-I is characterized by more frequent cranial nerve deficits, sensory disturbances, and ataxia. In addition, NCS findings revealed demyelinating neuropathy in a higher proportion of GBS-I cases than GBS-C cases. Furthermore, the frequency of AIDP was higher in GBS-I than in all GBS cases previously reported by a prospective cohort study in Japan (60% vs 40%).\textsuperscript{17} This is compatible with the results that GM1 and GD1a seropositivity rates were significantly more frequent in GBS-I compared with GBSRD-C. Besides, compared with cases with GBSRDs after \textit{M. pneumoniae} infection (GBSRD-M) reported recently,\textsuperscript{7} the clinical and serologic features of GBSRD-I were somewhat different from those of GBSRD-M, in which the anti-GQ1b antibody positive rate and the frequency of FS cases were lower, and the anti-Gal-C antibody positive rate was higher than in GBSRD-I.

**Table 3** Comparison of clinical characteristic between patients with GBS-I and GBS-C

| Features                      | GBS-I (n = 48) | GBS-C (n = 74) | p Value |
|-------------------------------|----------------|----------------|---------|
| Age median [range] (y)        | 32 [3–83]      | 35.5 [3–87]    | NS      |
| Sex (male/female)             | 26/22          | 37/37          | NS      |
| Antiglycolipid antibody positive | 14 (29%)      | 44 (59%)       | <0.01   |
| Cranial nerve deficits        | 22 (46%)       | 11 (15%)       | <0.01   |
| III, IV, and VI               | 8              | 2              |         |
| V                             | 3              | 1              |         |
| VII                           | 13             | 8              |         |
| IX and X                      | 9              | 8              |         |
| XI and XII                    | 7              | 5              |         |
| Severe muscle weakness (MMT <3) | 20 (42%)     | 33 (45%)       | NS      |
| Sensory disturbances          | 36 (75%)       | 34 (46%)       | <0.01   |
| Ataxia                        | 14 (29%)       | 3 (4%)         | <0.01   |
| Autonomic disturbance         | 10 (21%)       | 15 (20%)       | NS      |
| Peak FG                       | (n = 46)       | (n = 59)       |         |
| FG1                           | 4              | 10             |         |
| FG2                           | 11             | 12             |         |
| FG3                           | 11             | 5              |         |
| FG4                           | 13             | 26             |         |
| FG5                           | 7              | 6              | NS      |
| FG6                           | 0              | 0              |         |
| Electrophysiological examination | (n = 30)     | (n = 55)       |         |
| AMAN                          | 0 (0%)         | 13 (24%)       | <0.01   |
| AIDP                          | 18 (60%)       | 14 (25%)       | <0.01   |
| Unclassified                  | 12 (40%)       | 28 (51%)       | NS      |

**Abbreviations:** AIDP = acute inflammatory demyelinating polyneuropathy; AMAN = acute motor axonal neuropathy; FG = functional grade; GBS-C = Guillain-Barré syndrome after \textit{C. jejuni} infection; GBS-I = Guillain-Barré syndrome after influenza virus infection; MMT = manual muscle testing; NS = not significant.

differ significantly from patients with GBSRD-C (18%). Among the 15 patients with GBSRD-I seropositive for anti-GQ1b, 10 were diagnosed with FS. In patients with GBS-I, anti-GD1b was the most frequently detected autoantibody (7/48, 15%) (table 2).


different from those of GBSRD-M, in which the anti-GQ1b antibody positive rate and the frequency of FS cases were lower, and the anti-Gal-C antibody positive rate was higher than in GBSRD-I.

**Previous reports** (summarized in table 4) also found more frequent cranial nerve deficits (8/19, 42%) and sensory disturbance (15/19, 79%) in GBS-I. Moreover, these NCSs revealed demyelinating neuropathy in some patients with GBS-I (5/13, 38%), whereas axonal neuropathy was relatively less common (2/13, 15%).\textsuperscript{1,18–23} Those are in accord with the current findings.
Influenza viruses A and B are wrapped by a lipid bilayer envelope containing various glycoproteins, including HA and NA. Therefore, antiglycolipid antibodies may be produced by influenza virus infection because of possible molecular mimicry between glycoproteins of influenza viruses and glycolipids localized in human peripheral nerves.

The main limitation of this study is that we could not completely exclude the possible coexistence of other infections. Selection bias by attending physicians also could exist. In addition, we could not evaluate whether the severity and infection period of influenza virus infection are associated with the severity of GBS-I because the study was retrospectively conducted. A future prospective study is needed to clarify those issues. However, this study enrolled a relatively large number of patients, all with confirmed influenza infection. Therefore, clinical characteristics should reflect GBS-I and GBSRD-I.

In conclusion, antiglycolipid antibodies are detected in some GBSRD-I cases, and anti-GQ1b and anti-GT1a antibodies are the most frequent. Compared with GBS-C, GBS-I is characterized by more frequent AIDP, cranial nerve deficits, sensory disturbances, and ataxia. Further investigation is required to clarify the pathomechanisms of GBSRD-I.

**Author contributions**

M. Yamana has contributed to acquisition, analysis, and interpretation of data and drafted the manuscript. M. Kuwahara has analyzed and interpreted data and also participated in drafting the manuscript and revising it. Y. Fukumoto, K. Yoshikawa, and K. Takada have contributed to acquisition of data. S. Kusunoki has made substantial contributions to conception and design of the study and also revised the manuscript critically for important intellectual content. S. Kusunoki made final approval of the manuscript.

**Study funding**

This work was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan (Grants-in-Aid for Scientific Research, 18H02745), the Ministry of Health, Labour and Welfare of Japan (Health and Labour Sciences Research Grant on Rare and Intractable Diseases [Validation of Evidence-based Diagnosis and Guidelines, and Impact on QOL in Patients with Neuroimmunological Diseases]), and Intramural Research Grant (28-S) for Neurological and Psychiatric Disorders of NCNP.

**Disclosure**

None of the authors report any disclosures relevant to the manuscript. Disclosures available: Neurology.org/NN.

**Publication history**

Received by Neurology: Neuroimmunology & Neuroinflammation January 4, 2019. Accepted in final form April 5, 2019.

**References**

1. Jacobs BC, Rothbarth PH, van der Meché FGA, et al. The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology 1998;51:1110-1115.
2. Studahl M. Influenza virus and CNS manifestations. J Clin Virol 2003;28:225-232.
3. Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenza-like illness using the United Kingdom General Practice Research Database. Am J Epidemiol 2009;169:382-388.
4. Matsumoto H, Kobayashi O, Tamura K, Ohkawa T, Sekine I. Miller Fisher syndrome with transient coma: comparison with Bickerstaff brainstem encephalitis. Brain Dev 2002;24:98-101.
5. Hazr M, Morita A, Ichihara K, et al. Miller Fisher syndrome associated with influenza A infection. Intern Med 2012;51:2621-2623.
6. Hughes RA, Hadden RD, Gregson NA, Smith KJ. Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol 1999;100:74-97.
7. Kuwahara M, Samukawa M, Ikeda T, et al. Characterization of the neurological diseases associated with Mycoplasma pneumonia infection and anti-glycolipid antibodies. J Neurol 2017;264:467-475.
8. Ang CW, Laman JD, Willison HJ, et al. Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barre and Miller Fisher patients. Infect Immun 2002;70:1202–1208.

9. Kusunoki S, Shiina M, Kanazawa I. Anti-Gal-C antibodies in GBS subsequent to mycoplasma infection: evidence of molecular mimicry. Neurology 2001;57:736–738.

10. Ashbury AK, Comblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 1990;27(supp1):S21–S24.

11. Koga M, Kusunoki S, Kaida K, et al. Nationwide survey of patients in Japan with Bickerstaff brainstem encephalitis: epidemiological and clinical characteristics. J Neurol Neurosurg Psychiatry 2012;83:1210–1215.

12. Sakai-Tagawa Y, Ozawa M, Tamura D, et al. Sensitivity of influenza rapid diagnostic tests to H5N1 and 2009 pandemic H1N1 viruses. J Clin Microbiol 2010;48:2872–2877.

13. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911–1917.

14. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118(pt 3):597–605.

15. Kutlesa M, Santini M, Krajinović V, Raffanzelli D, Barsic B. Acute motor axonal neuropathy associated with pandemic H1N1 influenza A infection. Neurocrit Care 2010;13:98–100.

16. Vasconcelos A, Abecasis F, Monteiro R, et al. A 3-month-old baby with H1N1 and Guillain-Barré syndrome. BMJ Case Rep 2012;2012:bcr1220115462.
Guillain-Barré syndrome and related diseases after influenza virus infection
Masaki Yamana, Motoi Kuwahara, Yuta Fukumoto, et al.

Neurol Neuroimmunol Neuroinflamm 2019;6;
DOI 10.1212/NXI.0000000000000575

This information is current as of May 21, 2019